Register
Login:
Share:
Email Facebook Twitter

Member Info for bigbob0228


Member Since: Mon, 7th Apr 2008

Number of Share Chat Posts (all time): 96
Number of Share Chat Posts (last 30 days): 7

Last Posted: Today 07:53


Post Distribution over the last 30 days




Today 07:53


GW Pharmaceuticals to Report Q4, Year-End 2014 Financial Results and Host Conference Call on 2 December, 2014

LONDON, Nov. 24, 2014 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) ("GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will report on 2 December, 2014 its fourth quarter, year-end financial results for the period ending 30 September, 2014. GW will also host a conference call the same day at 8:00 a.m. EST/1:00 p.m. GMT.

Conference call information will be provided in the financial results press release. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 27 countries outside the United States. Sativex is also in Phase 3 clinical development as a potential treatment of pain associated with advanced cancer. This Phase 3 program has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) and is intended to support the submission of a New Drug Application for Sativex in cancer pain with the FDA and in other markets around the world. GW has a deep pipeline of additional cannabinoid product candidates, including Epidiolex® in the treatment of childhood epilepsy, which has received Fast Track Designation from the FDA for Dravet syndrome as well as Orphan Drug Designations from the FDA in both the treatment of Dravet syndrome and Lennox-Gastaut syndrome. GW's product pipeline also includes compounds in Phase 1 and 2 clinical development for glioma, ulcerative colitis, type 2 diabetes, and schizophrenia. For further information, please visit www.gwpharm.com.

Enquiries:

GW Pharmaceuticals plc(Today) +44 20 3727 1000

Justin Gover, Chief Executive Officer(Thereafter) + 44 1980 557000

Stephen Schultz, VP Investor Relations (U.S.)917 280 2424 / 401 500 6570



FTI Consulting (Media Enquiries)

Ben Atwell / Simon Conway / John Dineen (UK)+ 44 20 3727 1000

Robert Stanislaro (U.S.)212 850 5657



Trout Group, LLC (U.S. investor relations)

Todd James / Chad Rubin646 378 2900

Source: GW Pharmaceuticals plc
Wed 16:16


Well here we go again good news and the price should go up to $90 bad and we could see $70 again

Good luck all
Tue 17:54


Yes I too have been waiting all day for Q4 results o well very pleased that I topped up at 307 hope to start taking profit again at 500pps lets hope we finish the year on a high and we all have a happy Christmas

GL all

Bob
12 Nov '14


Almirall profits leap in first nine months of 2014

10-11-2014 COMMENTS (0)AlmirallAstraZenecaEkliraFinancialPharmaceuticalSpain

Facebook 0 Twitter 1 LinkedIn 0 Google+ 0

OTHER STORIES OF INTEREST

AstraZeneca to showcase inflammation/ autoimmunity pipeline at ACR11-11-2014FDA revokes tentative approval of Ranbaxy’s generic Nexium and Valcyte07-11-2014AstraZeneca’s olaparib shows success in tumor response rate for patients with BRCA-related cancers07-11-2014

RELATED NEWS FROM THE WEB

AstraZeneca battles pediatrician group over preemie drug guidelines28-07-2014Drug development is at risk from proposed takeover of AstraZeneca16-05-2014Pharmaceutical ETFs surge on M&A activity23-04-2014

RELATED COMPANIES

Almirall

AstraZeneca

Almirall (ALM: MC), Spain’s largest drugmaker, has reported strong financial results for the first-three quarters of 2014, with total revenues rising 7% to 654.1 million euros ($811.7 million).

Net sales for the nine months were 611.5 million euros, up 19.6%, with “other income” down 57.5% to 42.6 million euros. Gross profit leapt 27.6% to 429.8 million euros. Earnings before interest, taxes, depreciation and amortization (EBITDA) rocketed 80.4% to 107.0 million euros and net income was up 96.8% at 42.9 million euros. Nevertheless, Almirall’s shares dipped 1.2% to 12.96 euros in early trading this morning.

IN LINE WITH COMPANY GUIDANCE

Eduardo Sanchiz, chief executive, said: “Performance for September YTD [year-to-date] has been strong and in line with our guidance for the year, showing high teens growth in sales and very significant profits growth, all driven primarily by respiratory and dermatology together with our other platforms of growth, gastroenterology and pain.”

He continued: “We see now, effective on November 1, a significant evolution in Almirall's strategy through our strategic respiratory agreement with AstraZeneca. This deal will allow to maximize the value of our respiratory portfolio and for Almirall to be able to obtain over the years a revenue stream linked to its performance. At the same time, the proceeds from this operation will help us to better focus in specialty areas and particularly in dermatology, where we are taking further efforts to become a top global player.”

PLATFORMS OF GROWTH

In the third quarter, Almirall’s growth continued to be driven by a strong focus in respiratory and dermatology followed by gastroenterology and pain.

Sales of chronic obstructive pulmonary disease (COPD) drug Eklira (aclidinium bromide) grew to 93.4 million euros (+53.3%), representing 15.3% of net sales.

The Dermatology franchise grew 83.4% to 181.9 million euros following the consolidation of Aqua Pharmaceuticals (+6% excluding Aqua), and it has now become the firm’s number one therapeutic area in terms of sales. In prescription dermatology, Almirall is already number one in Germany, number five in Europe


Sign up for Live Prices
Top Recommended
Hot Chat Topics
Top recommended posters in the last 30 days
Share Price SpacerBrotherhumble680 
Share Price Spaceroptrade662 
Share Price Spaceronceatrader624 
Share Price SpacerK3VMC436 
Share Price SpacerBelcourtoi418 
Share Price Spacermatlot410 
Share Price SpacerGrumpyScouser398 
Share Price Spacerrobbajob396 




Member Login

Forgotten your password?
Email:

Password:


Don't have an account? Click here to Register Free!


Home  |  Contact Us  |  About Us  |  Careers  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.